Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Free Trial Request
Subscribe
Advertising
UsernamePublicRestriction
Tags:
BioPharmaceutical Reimbursement Market Access

Reining In “March In”: NIH Rejects Xtandi Petition

This article was originally published in RPM Report

Executive Summary

The National Institutes of Health is rejecting calls to exercise “march in” rights on patents for a cancer drug, declaring its view that the authority is narrowly focused on shortages – not pricing.

Table

View full table

Advertisement

Related Content

Pink Sheet
NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’

Topics

Related Companies

Related Deals

What to read next

Advertisement
Tags:
BioPharmaceutical Reimbursement Market Access
UsernamePublicRestriction

Register

PS079947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By